New quinolones and the impact on resistance

Drug Discovery Today

Volumn 6, Issue 10, 2001, Pages 529-536

  Dougherty, Thomas J ^a   Beaulieu, Danielle ^a   Barrett, John F ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; QUINOLONE DERIVATIVE; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; DRUG DEVELOPMENT; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW;

EID: 0035337321     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(01)01760-3     Document Type: Review

References (57)

1. Breithaupt H. The new antibiotics. Nat. Biotechnol. 17:1999;1165-1169.
2. Wise R. A review of mechanisms of action and resistance of antimicrobial agents. Can. Respir. J. 6:(Suppl: A):1999;20A-22A.
3. Stefani S., Agodi A. Molecular epidemiology of antibiotic resistance. Int. J. Antimicrob. Agents. 13:2000;143-153.
4. Martinez L., et al. Quinolone resistance from a transferable plasmid. Lancet. 351:1998;797-799.
5. Drlica K., Zhao R. DNA gyrase, topoisomerase IV and the 4-quinolones. Microbiol. Mol. Biol. Revs. 61:1997;377-392.
6. Drlica K. Mechanism of fluoroquinolone action. Curr. Opin. Microbiol. 2:1999;504-508.
7. Reece R., Maxwell A. DNA gyrase: structure and function. Crit. Rev. Biochem. Mol. Biol. 26:1991;335-375.
8. Sugino A., et al. Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc. Natl. Acad. Sci. USA. 74:1977;4767-4771.
9. Gellert M., et al. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc. Natl. Acad. Sci. USA. 74:1977;4772-4776.
10. Kampranis S.C., Maxwell A. The DNA gyrase-quinolone complex: ATP hydrolysis and the mechanism of DNA cleavage. J. Biol. Chem. 273:1998;22615-22626.
11. Kato J-L., et al. New topoisomerase essential for chromosome segregation in E. coli. Cell. 63:1990;393-404.
12. Khodursky A.B., et al. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc. Natl. Acad. Sci. USA. 92:1995;11801-11805.
13. Blanche R., et al. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob. Agents Chemother. 40:1996;2714-2720.
14. Marians K.J., Hiasa H. Mechanism of quinolone action. A drug-induced structural perturbation of the DNA precedes strand cleavage by topoisomerase IV. J. Biol. Chem. 272:1997;9401-9409.
15. Anderson V.E., et al. Topoisomerase catalysis and the mechanism of quinolone action. J. Biol. Chem. 273:1998;17879-17885.
16. Khodursky A.B., Cozzarelli N.R. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J. Biol. Chem. 273:1998;27668-27677.
17. Piddock L.J.V. Mechanism of fluoroquinolone resistance: An update 1994-1998. Drugs. 58:(Suppl. 2):1999;11-18.
18. Hooper D.C., Wolfson J.S. Quinolone Antimicrobial Agents. 2nd edition :1993;American Society for Microbiology, Washington DC.
19. Andriole V.T. The Quinolones. 2nd edition :1998;Academic Press.
20. Goldstein F.W., Acar J.F. Epidemiology of quinolone resistance: Europe and North and South America. Drugs. 49:(Suppl. 2):1995;36-42.
21. Fluit A.C., et al. Antimicrobial resistance among urinary tract infection (UTI) isolates in Europe: Results from the SENTRY Antimicrobial Surveillance Program. Antonie van Leeuwenhoek Int. J. 77:1997;147-152.
22. Diekema D.J., et al. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin. Infect. Dis. 29:1997;595-607.
23. Fluit A.C., et al. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin. Infect. Dis. 30:2000;454-460.
24. Gales A.C., et al. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program, 1998. J. Antimicrob. Chemother. 45:2000;295-303.
25. Schmitz F.J., et al. Comparative activities of six different fluoroquinolones against 9,682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance programme. The SENTRY participants group. Int. J. Antimicrob. Agents. 12:1999;311-317.
26. Hooper D.C. Mechanisms of quinolone resistance. Drug Resist. Updates. 2:1999;38-55.
27. Jones R.N. Perspectives on the development of new antimicrobial agents for resistant Gram-positive pathogens. Braz. J. Infect. Dis. 4:2000;1-8.
28. Adams D., et al. The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication. Cell. 71:1992;277-288.
29. Crisona N.J., et al. Preferential relaxation of positively supercoiled DNA by E. coli topoisomerase IV in single-molecule and ensemble measurements. Genes Dev. 14:2000;2881-2892.
30. Roca J. The mechanisms of DNA topoisomerases. Trends Biochem. Sci. 20:1995;156-160.
31. Nakamura S., et al. GyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrob. Agents Chemother. 33:1989;254-255.
32. Nakamura S. Mechanisms of quinolone resistance. J. Infect. Chemother. 3:1997;128-138.
33. Fass D., et al. Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands. Nat. Struct. Biol. 6:1999;322-326.
34. Peng H., Marians K. The interaction of Escherichia coli topoisomerase IV with DNA. J. Biol. Chem. 270:1995;25286-25290.
35. Hoshino K., et al. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob. Agents Chemother. 38:1994;2623-2627.
36. Ferrero L., et al. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:1994;641-653.
37. Munoz R., de la Campa A.G. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:1996;2252-2257.
38. Pan X-S., et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:1996;2321-2326.
39. Pan X-S., Fisher L.M. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:1998;2810-2816.
40. Pan X-S., Fisher L.M. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: Overexpression, purification and differential inhibition by fluoroquinolones. Antimicrob. Agents Chemother. 43:1999;1129-1136.
41. Chen C-R., et al. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J. Mol. Biol. 258:1996;627-637.
42. Rattan A. Mechanisms of resistance to fluoroquinolones. Natl. Med. J. India. 12:1999;162-164.
43. Lawrence L.E., Barrett J.F. Inhibition of bacterial efflux: needs, opportunities and strategies. Current Opin. Anti-Infective Invest. Drugs. 2:2000;145-153.
44. Ng E.Y.W., et al. Quinolone resistance mediated by NorA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob. Agents Chemother. 38:1994;1345-1355.
45. Hooper D.C. Clinical applications of quinolones. Biochim. Biophys. Acta. 1400:1998;45-61.
46. Markham P.N., et al. Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1999;2404-2408.
47. Alcala L., et al. In vitro activity of the new quinolone moxifloxacin (Bay128039) against resistant Gram-positive clinical isolates. Diagn. Microbiol. Infect. Dis. 33:1999;27-31.
48. Pestova E., et al. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J. Antimicrob. Chemother. 45:2000;583-590.
49. Lee A., et al. Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J. Bacteriol. 182:2000;3142-3150.
50. Gill M.J., et al. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:1999;187-189.
51. Pong A., et al. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J. Antimicrob. Chemother. 44:1999;621-627.
52. Dalhoff A., et al. In vitro activity of BAY128039, a new methoxyquinolone. Chemotherapy. 42:1996;410-425.
53. Lu T., et al. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob. Agents Chemother. 43:1999;2969-2974.
54. Takahata M., et al. In vitro and in vivo antimicrobial activities of T3811, a novel des-F(6)-quinolone. Antimicrob. Agents Chemother. 43:1999;1077-1084.
55. Blondeau J.M., et al. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 45:2001;433-483.
56. Sindelar G., et al. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob Agents Chemother. 44:1999;3337-3343.
57. Zhao X., et al. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. USA. 94:1997;13991-13996.